Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hangzhou Just Biotherapeutics (Just China)

Request full access

Hangzhou Just Biotherapeutics is a comprehensive high-tech design company

Hangzhou, ChinaFounded 2015Biotech & Life Sciences

About Hangzhou Just Biotherapeutics (Just China)

Hangzhou Just Biotherapeutics (HJB), operating as the contract development and manufacturing organization (CDMO) arm of Transcenta Holding Limited, provides specialized services for large-molecule biotherapeutics. The company was founded in August 2016 by Dr. Jonathan Y. Zhao, a former executive at Amgen, along with other industry veterans. HJB was established as a sister company to the Seattle-based Just Biotherapeutics Inc., which was co-founded by Dr. Zhao and other Amgen alumni in 2015.

In a significant milestone, HJB merged with MabSpace Biosciences in January 2019 to form Transcenta Holding Ltd., creating a fully integrated biotherapeutics company. This strategic merger combined HJB's process development and manufacturing strengths with MabSpace's discovery and clinical research capabilities. Following the merger, Dr. Jonathan Y. Zhao assumed the role of executive chairman, while Dr. Xueming Qian, the founder of MabSpace, became the CEO of Transcenta. Transcenta successfully completed its initial public offering on the Hong Kong Stock Exchange on September 29, 2021.

The company's business model is centered on providing end-to-end CDMO services to biotechnology and pharmaceutical firms, covering the entire lifecycle from development to manufacturing. HJB generates revenue by offering a comprehensive suite of services, including cell line and process development, analytical services, formulation, and both drug substance (DS) and drug product (DP) manufacturing under cGMP standards. Its clientele consists of companies requiring accelerated development and cost-effective manufacturing for their biologic drug candidates for preclinical studies through to commercial launch. HJB operates in the global biopharmaceutical CDMO market, with facilities in Hangzhou, China, designed to meet international quality standards.

HJB's core service is anchored by advanced technology platforms designed to accelerate timelines and reduce production costs. A key feature is its modular manufacturing facility (T-BLOC) and the implementation of an Integrated Continuous Bioprocessing (HiCB) platform. These systems are designed to enhance efficiency, improve process control, and lower the cost of goods for complex biologics like monoclonal antibodies and fusion proteins. The service portfolio is extensive, ranging from initial material generation for research and developability assessment to late-stage process characterization and regulatory filing support for IND applications in both China and the US.

Source: Dealroom company data

At a glance

Status
Operational
Employees
165
Open positions
None listed
Dealroom signal
46.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jun 2018 $35M $140M Undisclosed —
SERIES BOther financing Aug 2017 $55M $220M Temasek · ARCH Venture Partners · Lilly Asia Ventures · Bank of China —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Hangzhou Just Biotherapeutics (Just China) website traffic

Latest recorded traffic for Hangzhou Just Biotherapeutics (Just China) is 430 monthly website visits, up 115% over the last three months. Hangzhou Just Biotherapeutics (Just China)'s team grew 3.1% over the past year.

Latest monthly visits430 3-month web change+115% 1-year team growth+3.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Hangzhou Just Biotherapeutics (Just China) in the Hangzhou ecosystem

Live from Dealroom

The Hangzhou Just Biotherapeutics (Just China) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Bill & Melinda Gates Foundation

Series A5 investors entered at this stage

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇨🇳 China75%
🇧🇷 Brazil8.3%
🇺🇸 United States8.3%
🇹🇼 Taiwan8.3%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hangzhou Just Biotherapeutics (Just China) on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hangzhou Just Biotherapeutics (Just China)’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.